Abstract
Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP–CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain.
| Original language | English |
|---|---|
| Pages (from-to) | 4552-4553 |
| Number of pages | 2 |
| Journal | Clinical Cancer Research |
| Volume | 30 |
| Issue number | 20 |
| DOIs | |
| State | Published - Oct 15 2024 |
Fingerprint
Dive into the research topics of 'Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver